The incorporation of patient-reported outcomes (PROs) is essential for assessing whether a cancer treatment enhances overall patient well-being, beyond merely extending survival. This scoping review aimed to identify and analyze the use of PROs in ovarian cancer clinical trials.

Hypoxic-ischemic encephalopathy (HIE) continues to be an important cause of long-term neurologic disability among newborn infants. The estimated incidence ranges from 2-3/1000 live births in developed countries, to as high as 10-20/1000 in developing countries [1]. Affected infants who survive are at a 25% risk for cerebral palsy, epilepsy, and cognitive deficits and may require lifelong medical care.

In early 2020, the contagious and deadly virus, SARS-CoV-2, was identified. The virus spread rapidly worldwide and was declared a pandemic by the World Health Organization (WHO) in March of 2020 [1]. While many who became infected remained asymptomatic, an alarming number of infected individuals developed severe symptoms, often requiring hospitalization and intensive care, or resulting in death.

Intensive care unit (ICU) admissions have increased considerably in the last decade. A group of patients that remains poorly characterized are the ones who die within the first 24 hours following ICU admission.